Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Complement-C1 inhibitor protein - Octapharma

Next Previous
Search
Drug Profile

Complement-C1 inhibitor protein - Octapharma

Alternative Names: C1 Esterase inhibitor - Octapharma; Human plasma derived C1 Esterase inhibitor - Octapharma; OCTA-C1-INH

Latest Information Update: 15 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Octapharma
  • Class Anti-ischaemics; Antianaemics; Complement C1 inactivator proteins; Eye disorder therapies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hereditary angioedema

Most Recent Events

  • 30 Apr 2024 Phase-III clinical trials in Hereditary angioedema (In adolescents, In adults, In children, In the elderly) in Romania (IV) (NCT06361537)
  • 12 Apr 2024 Octapharma plans a phase III trial for Hereditary angioedema (In children, In adolescents, In adults, In the elderly) (IV, Injection) in April 2024 (NCT06361537)
  • 17 Feb 2021 Octapharma completes a phase II trial in Hereditary angioedema in Belarus, Russia, Ukraine and Germany (IV) (ISRCTN36746902) (EudraCT2019-001693-28)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top